WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Iran helicopter crash that killed President Raisi could reverberate across the Middle East
Tigers and Cardinals rained out, will play a traditional doubleheader on Tuesday
Real Madrid coach Carlo Ancelotti apologizes for forgetting German on his Bayern Munich return
House and Senate negotiate on bill to assist FAA
Turner hits 2 home runs, Jansen also connects as Blue Jays beat Royals 6
New Mexico reaches record settlement over natural gas flaring in the Permian Basin
Why International Criminal Court has Israeli officials worried
Adams, Reyna, Turner, Ream are US concerns ahead of Copa America
A second new nuclear reactor is completed in Georgia. The carbon
Dodgers acquire pitcher Yohan Ramírez from Mets for cash
Analysis: The NHL playoffs are off to an odd start, from the net out